| Document |
Document Title |
|
WO/2024/075025A1 |
The present invention relates to an industrial process for the preparation of 2,3-O-Isopropylidene-D-ribofuranose of formula (I). The intermediate of formula (I) is used for the preparation of Varitriol, Carbovir, Abacavir, Sapropterin d...
|
|
WO/2024/050809A1 |
Provided is a method for the glycosylation modification of proteins and/or polypeptides, belonging to the technical field of medicinal chemistry. Using glycosyl sulfinate as a raw material, a method for the glycosylation modification of ...
|
|
WO/2023/213035A1 |
Disclosed is a method for preparing an aryl carbon glycoside compound including a gliflozin drug, belonging to the technical field of pharmaceutical chemistry. According to the present invention, a sulfinate glycosyl donor represented by...
|
|
WO/2023/213034A1 |
Disclosed are a sulfinate glycosyl donor, a method for preparing same, and use thereof, belonging to the technical field of pharmaceutical chemistry. The present invention particularly provides a sulfinate glycosyl donor represented by f...
|
|
WO/2023/212746A2 |
As disclosed here, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. These macrocycles can be used to as chemotherapeutic agents.
|
|
WO/2023/198682A1 |
Compound of the general formula (Ia), (Ib) and (Ic) R50 and R60 are different form each other and are selected from the group consisting of -R70, -ZR70, -Z-OH, -Z-NH2, -Z-SH, -Z-OC(O)R70, -OC(O)R70, - COOH and its corresponding salts, -C...
|
|
WO/2023/197791A1 |
The present invention relates to a cyclic carbonate nucleoside compound as represented by formula (I), and a pharmaceutically acceptable salt, a crystalline hydrate, a solvate or a tautomer thereof, and further disclosed are a pharmaceut...
|
|
WO/2022/223480A1 |
The present invention relates to Use of a compound of the general formula (I), (II), (III), (IV), (V) or (VI) wherein R1 and R1', R21 and R21', R31 and R31' are the same and are hydrogen, a linear or branched C1 to C18 alkyl, a linear or...
|
|
WO/2022/204907A1 |
Provided is a method for preparing a cocrystal of L-pyroglutamic acid and a glucopyranosyl derivative, which can be used as a sodium-dependent glucose transporter (SGLT) inhibitor. The method is stable and controllable, so the target coc...
|
|
WO/2022/125735A1 |
The disclosure provides processes for preparing the compound of formula (VIII) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIII) are also provided.
|
|
WO/2022/094711A1 |
Disclosed is a process of preparation of a compound of formula 13, and intermediates prepared and used in the preparation of the compound of formula 13.
|
|
WO/2022/078487A1 |
The present disclosure provides a zolinose compound represented by formula (I), a preparation method therefor and a use thereof, wherein definitions of substituents are provided in the description. The zolinose compound has application p...
|
|
WO/2022/007838A1 |
A method for preparing glucopyranosyl derivatives as sodium dependent glucose cotransporter (SGLT) inhibitors, an intermediate thereof, and a method for preparing the intermediate. The method has simple operation, simple post-treatment, ...
|
|
WO/2021/216427A1 |
Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.
|
|
WO/2021/216722A1 |
The present invention provides stereoselective processes of manufacture for the phosphoramidate nucleotide Compound 1 or a pharmaceutically acceptable salt thereof.
|
|
WO/2021/121270A1 |
A method for purifying an SGLTs inhibitor and an application thereof. The SGLTs inhibitor is (1S,2S,3S,4R,5S)-5-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)
methyl)-4- ethyl phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,
4-tri...
|
|
WO/2021/095741A1 |
Provided is a cryoprotectant capable of inhibiting cytotoxicity, even in the presence of a cryoprotectant such as DMSO. Specifically provided is a compound represented by formula I-1 or I-2, or a salt or a solvate thereof. [In the form...
|
|
WO/2021/074211A1 |
Described is a compound having the structure (I), (II) or (V), Formulae(I), (II), (V), wherein R1 is –H, –CH2OH or –CH(OH)CH2OH; R2 is –H, -OH, or –CH2OH; R3 is –H, -OH, or –CH2OH; n is 0 or 1; p is 0 or 1; R10 is hydrogen ...
|
|
WO/2021/076630A1 |
In certain embodiments a platform technology for the facilitating immune therapy in the treatement of cancer is provided. In certain embodiments nanocarriers are provided that facilitate delivery of an IDO inhibitor in conjunction with a...
|
|
WO/2021/015622A1 |
The current invention concerns methods for the synthesis of 6-azido-6-deoxy-2-N-acetyl-monosaccharide-nucleoside diphosphate, in particular 6-azido-6-deoxy-2-N-acetyl-D- galactosamine-nucleoside diphosphate or 6-azido-6-deoxy-2-N-acetyl-...
|
|
WO/2021/004498A1 |
It relates to glucopyranosyl derivative of formula (I) as a sodium-dependent glucose transporters1 (SGLT1) inhibitor, a pharmaceutically acceptable salt, or a stereoisomer thereof, and further relates to a pharmaceutical composition cont...
|
|
WO/2020/248068A1 |
The present application provides a synthetic method for production of 3-azido-3-deoxy-D-galactopyranose. Also provided are methods of using the 3-azido-3-deoxy-D-galactopyranose in the manufacture of galactoside galectin antagonists, suc...
|
|
WO/2020/143653A1 |
Provided are a preparation method for a glucopyranosyl derivative compound used as an inhibitor of a sodium-dependent glucose transporter (SGLT) and an important intermediate of the glucopyranosyl derivative compound. The preparation met...
|
|
WO/2020/001812A1 |
The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.
|
|
WO/2019/224172A1 |
The present invention relates to the manufacture of allofuranose from glucofuranose as defined in the description and in the claim. Allofuranos is an intermediate in the manufacture of oligonucleotides which can be used as a medicament.
|
|
WO/2019/221752A1 |
This invention relates to a method for inhibiting egg yolk gelation resulting from freezing and thawing. This method comprises treating egg yolk with an effective amount of a compound selected from the group consisting of amino acids, hy...
|
|
WO/2019/179325A1 |
The present invention relates to the field of carbohydrate chemistry, and discloses a preparation method for a surface capsular polysaccharide structural derivative of Gram-positive bacteria. In the present invention, glucose is used as ...
|
|
WO/2019/169988A1 |
The present invention relates to the field of pharmaceutical chemistry, and in particular, to the crystal forms of Ertugliflozin and preparation methods therefor. Said crystal form is crystal form I, crystal form II or crystal form III, ...
|
|
WO/2019/149178A1 |
The present invention relates to a glucopyranosyl derivative and a use thereof. In particular, the present invention relates to a glucopyranosyl derivative that is used as an inhibitor of sodium-dependent glucose transporters (SGLTs), pa...
|
|
WO/2019/119117A1 |
There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis...
|
|
WO/2019/053700A2 |
Probe embodiments for identifying analytes involved in biofuel or bioenergy production, bioremediation, or nutrient cycling as well as methods of making and use are described herein. In some embodiments, probes identifying cellulose degr...
|
|
WO/2018/074926A1 |
The present invention relates to new bi-functional and polyfunctional bis- dioxolanes and bis-dioxanes. The present inventors have established that the bis- dioxolanes and bis-dioxanes of the invention are highly advantageous as building...
|
|
WO/2018/055496A1 |
The present invention relates to a process for the preparation of crystalline Form G1 of Ertugliflozin (1). (I) The invention also relates to crystalline Form G l obtained by the process of the present invention, the said Form Gl being s...
|
|
WO/2017/190568A1 |
Disclosed are an amine solvate of a sodium-glucose linked transporter (SGLT) inhibitor, and a preparation method and application thereof. The SGLT inhibitor is (1S,2S,3S,4R,5S)-5-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)
methyl)-4-ethylb...
|
|
WO/2017/178513A1 |
The present invention relates to a method for preparing monomers via depolymerisation from lignocellulose-containing biomass.
|
|
WO/2017/134606A1 |
The present invention relates to a crystalline Form B of {(1 R,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxybenzylphenyl]- 2,3,4-trihydroxy- 6,8-dioxabicyclo [3.2. 1]oct-1-yl}methyl acetate of Formula (II) and a process for its preparation. The p...
|
|
WO/2017/088839A1 |
This present invention relates to a complex of a glucopyranosyl derivative and L-pyroglutamic acid as a sodium dependent glucose cotransporter (SGLT) inhibitor, and preparation processes thereof, and a pharmaceutical composition containi...
|
|
WO/2017/085144A1 |
The invention relates to new compounds of formulae: Wherein: R 1 and R 2 can be independently H; a C 1 to C 6 alkyl including methyl, ethyl, propyl, butyl; aryl including phenyl, para-methoxyphenyl; or R 1, R 2 together with the carbon C...
|
|
WO/2017/047816A1 |
The present invention provides a method for producing guanidine crosslinked artificial nucleic acid (abbreviated hereinafter as GuNA), and an intermediate compound for the production thereof. Specifically, the present invention provides ...
|
|
WO/2017/034004A1 |
[Problem] To provide a novel gelling agent containing a sugar derivative. [Solution] A gelling agent comprising a compound represented by the formula (1) or (2). (in the formulae: R1 represents a C9-20 straight or branched alkyl, a C13-2...
|
|
WO/2016/173425A1 |
This present invention relates to a glucopyranosyl derivative as sodium dependent glucose cotransporters (SGLTs) inhibitor, preparation processes thereof, and pharmaceutical uses thereof, pharmaceutical compositions containing the compou...
|
|
WO/2016/050134A1 |
Provided are an L-proline compound of a sodium-glucose cotransporter 2 inhibitor, and a monohydrate and a crystal of the L-proline compound. Specifically, provided are 1,6-dehydrated-1-C{4-chloro-3-[(3-fluoro-4-ethoxyphenyl)meth
yl]pheny...
|
|
WO/2016/000599A1 |
Disclosed are a C-benzo five-membered heteroaromatic ring aryl glucoside derivative represented by general formula (I), a preparation method for the derivative or an intermediate thereof, and a use of the derivative, wherein R, R1, R2, R...
|
|
WO/2015/137838A1 |
A compound of formula I : or a salt thereof, wherein: R1 is -OC(H) (X) (CH2)nC(=O)OH; R2 is -OH, -N3, or -N (H) C (=O) CH3; or R1 and R2 together with the carbon atoms to which they are attached form R3 is -H, -CH3, -CH2C(=O)OH, or -CH2O...
|
|
WO/2015/109049A1 |
Provided herein are glycomimetic E-selectin antagonist compounds of formula (I)) and pharmaceutical compositions comprising at least one of the same. The compounds of the present disclosure include trisaccharide domain mimics comprising ...
|
|
WO/2015/043473A1 |
Provided herein are glucopyranosyl derivatives used as sodium dependent glucose cotransporters (SGLTs) inhibitors and pharmaceutical uses thereof, particularly 6,8-dioxabicyclo [3.2.1] octane derivatives represented by Formula (I), or ph...
|
|
WO/2015/032272A1 |
The present invention relates to a C-aryl glucoside derivative, a preparation method for same, and medical applications thereof. Specifically, the present invention relates to compounds as represented by formula I, and, tautomers, enanti...
|
|
WO/2015/027963A1 |
The present invention relates to an aromatic ring derivative, and pharmaceutical composition and use thereof, in particular to aromatic ring derivatives or hydrates as represented by general formula (II), solvates, stereoisomers thereof,...
|
|
WO/2014/132468A1 |
Provided is a sugar chain compound as mentioned in item (a) or (b), which contains a 1,2-cis-type sugar residue: (a) a polysaccharide or oligosaccharide formed by repeatedly binding a sugar unit represented by formula (I) or (I'); and (b...
|
|
WO/2014/125967A1 |
The present invention addresses the problem of providing a highly-versatile method for easily producing α-O-pyranosides with a high degree of selectivity without establishing severe reaction conditions, and a pyranose donor used in said...
|
